Literature DB >> 11378352

Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir).

H L Sham1, D A Betebenner, T Herrin, G Kumar, A Saldivar, S Vasavanonda, A Molla, D J Kempf, J J Plattner, D W Norbeck.   

Abstract

The HIV protease inhibitor ABT-378 (Lopinavir) is metabolized rapidly and extensively by CYP-3A4 catalyzed oxidation. Three of the major metabolites identified were synthesized and their antiviral (HIV) activities determined.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11378352     DOI: 10.1016/s0960-894x(01)00243-8

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

Review 1.  Adherence-resistance relationships to combination HIV antiretroviral therapy.

Authors:  David R Bangsberg; Deanna L Kroetz; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2007-05       Impact factor: 5.071

2.  Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans.

Authors:  Gondi N Kumar; Venkata K Jayanti; Marianne K Johnson; John Uchic; Samuel Thomas; Ronald D Lee; Brian A Grabowski; Hing L Sham; Dale J Kempf; Jon F Denissen; Kennan C Marsh; Eugene Sun; Stanley A Roberts
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

3.  Synthesis and Characterization of Impurities in the Production Process of Lopinavir.

Authors:  Ambati V Raghava Reddy; Srinivas Garaga; Chandiran Takshinamoorthy; Andra Naidu
Journal:  Sci Pharm       Date:  2014-09-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.